Description

Product Description

Palbociclib is a high-purity selective CDK4/6 inhibitor specifically designed for laboratory research and in vitro mechanistic studies. Supplied at 125 mg per vial, it provides researchers with a reliable and reproducible reagent for studying cell cycle regulation, kinase-mediated signaling pathways, and protein interaction dynamics under strictly controlled laboratory conditions. Its well-characterized chemical properties and high purity make it an ideal tool for biochemical assays, enzymatic inhibition studies, and mechanistic pathway analyses.

Manufactured under strict quality control procedures in a GMP-compliant facility, Palbociclib ensures batch-to-batch consistency, which is critical for longitudinal studies, comparative assays, and high-throughput screening (HTS) applications. Each vial undergoes rigorous analytical verification, including HPLC, NMR, and mass spectrometry, ensuring chemical integrity, purity, and experimental reliability. Researchers can confidently incorporate Palbociclib into in vitro experimental designs without variability concerns that could compromise data quality.

Palbociclib enables detailed exploration of CDK4/6-mediated regulatory mechanisms, including phosphorylation of retinoblastoma protein (Rb) and modulation of downstream cell cycle signaling networks. It can be used in cell-free enzymatic assays, recombinant protein platforms, and mechanistic pathway models, providing a high-resolution view of molecular interactions and allowing for precise mechanistic dissection of kinase-mediated processes.

This small-molecule inhibitor also facilitates structure–function relationship (SFR) studies, where variations in inhibitor concentration, binding affinity, or conformational dynamics can be assessed. When integrated with computational docking, molecular simulations, or predictive modeling, Palbociclib provides a robust framework for in silico and in vitro correlation, enhancing mechanistic insight and supporting hypothesis generation.

Each batch of Palbociclib is supplied with a Certificate of Analysis (COA) and supporting analytical documentation, ensuring reproducibility and traceability. Its high purity, consistent formulation, and compatibility with multi-omic and computational approaches make Palbociclib an essential research reagent for laboratories conducting protein interaction studies, kinase pathway analyses, and detailed mechanistic exploration.

In summary, Palbociclib 125 mg is a versatile, high-purity tool for experimental research, providing precise, reproducible, and mechanistically informative data in strictly controlled in vitro studies. Its application spans kinase inhibition, cell cycle regulation, signaling pathway dissection, and integration with computational modeling, bridging experimental assays with advanced molecular research workflows.

Product Specifications

Notes

Palbociclib is highly purified and carefully characterized to ensure suitability for in vitro mechanistic studies such as kinase inhibition assays, cell cycle regulation research, and signaling pathway reconstruction. Its crystalline powder form allows accurate weighing and precise preparation of stock solutions for controlled laboratory experiments.

The product is manufactured under GMP-compliant conditions, guaranteeing high reproducibility and minimal batch-to-batch variability. Each batch is analytically verified, ensuring chemical stability, consistent inhibitory potency, and suitability for protein interaction studies, high-throughput screening, and mechanistic exploration.

Palbociclib’s storage and handling recommendations are optimized to maintain integrity, with protection from light, moisture, and extreme temperatures. Proper adherence to these guidelines preserves activity and purity, enabling reproducible results in experimental assays, mechanistic pathway studies, and structure–function analyses.

Researchers can also use Palbociclib in combination with computational modeling and multi-omic approaches to enhance mechanistic insight. Its reliable performance and high purity make it an ideal reagent for laboratories conducting precision kinase research, signaling pathway dissection, and in vitro protein interaction studies.

Mechanism of Action

Palbociclib functions as a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, providing a precise tool for in vitro mechanistic studies of cell cycle regulation. By inhibiting CDK4/6 activity, Palbociclib prevents the phosphorylation of the retinoblastoma protein (Rb), allowing researchers to dissect G1-to-S phase transition mechanisms and downstream signaling cascades in controlled laboratory systems.

In cell-free assays and recombinant protein platforms, Palbociclib enables detailed investigation of kinase-substrate interactions, phosphorylation dynamics, and pathway modulation. Researchers can study the temporal effects of kinase inhibition, measuring both immediate and sustained impacts on target proteins, and evaluate conformational or structural changes induced by inhibitor binding.

Palbociclib also supports structure–function relationship (SFR) analyses, allowing researchers to explore binding specificity, inhibitory potency, and molecular interaction sites. Combined with spectroscopic techniques, high-resolution imaging, or computational docking, these studies can reveal mechanistic insights into target engagement, protein stability, and functional inhibition.

Integration with in silico modeling and predictive simulations further enhances the mechanistic understanding of Palbociclib’s action. Researchers can correlate experimental inhibition data with computational predictions, providing robust validation of observed effects and allowing detailed exploration of molecular pathways and regulatory nodes.

Overall, Palbociclib acts as a highly reliable research reagent for laboratories studying CDK-mediated regulatory networks, cell cycle checkpoints, and kinase-dependent signaling pathways. Its high purity and reproducibility ensure that experimental results are consistent and interpretable, making it a versatile tool for biochemical assays, protein interaction studies, and mechanistic pathway reconstruction in strictly controlled in vitro research environments.

Applications

Kinase Inhibition Studies

Palbociclib is widely used in in vitro kinase inhibition assays, enabling researchers to evaluate CDK4/6 activity, substrate phosphorylation, and downstream pathway modulation. Its high purity ensures reproducible results across multiple experimental setups, supporting mechanistic investigation of kinase regulation.

Cell Cycle Regulation Research

In laboratory-constructed cell cycle models, Palbociclib allows detailed examination of G1-to-S phase transition mechanisms, Rb phosphorylation dynamics, and checkpoint controls. Researchers can precisely dissect molecular interactions and regulatory feedback loops without interference from in vivo variables.

Signaling Pathway Analysis

Palbociclib is applied in recombinant protein platforms and cell-free systems to study complex signaling pathways influenced by CDK4/6 activity. It facilitates controlled experiments for mechanistic pathway reconstruction, protein-protein interaction mapping, and temporal signaling analysis, providing insights into kinase-dependent molecular networks.

High-Throughput Screening and Comparative Studies

The compound serves as a reference inhibitor in high-throughput screening (HTS) assays, helping laboratories validate assay sensitivity, reproducibility, and response dynamics. Its predictable performance supports comparative evaluation of new inhibitors and mechanistic assay benchmarking.

Structure–Function Relationship (SFR) Studies

Palbociclib supports epitope mapping, binding affinity assessments, and conformational analyses in vitro. Combined with spectroscopic techniques, imaging methods, and computational docking, it provides comprehensive mechanistic insight into molecular interactions and inhibitory specificity.

Multi-Omic Integration

The compound can be integrated into proteomics, transcriptomics, and metabolomics workflows, enabling correlation of CDK4/6 inhibition with pathway-level responses. This integration supports holistic mechanistic analysis, hypothesis generation, and predictive modeling in controlled laboratory research.

Overall, Palbociclib offers a versatile and reliable tool for laboratories conducting protein interaction studies, kinase inhibition research, cell cycle analysis, and integrative mechanistic experiments, ensuring precise, reproducible, and high-resolution data in in vitro studies.

Research Models

Cell-Free Protein Systems

Palbociclib is frequently employed in cell-free protein systems, allowing researchers to analyze CDK4/6 activity, substrate phosphorylation, and regulatory interactions under tightly controlled conditions. These models provide quantitative insights into kinase inhibition dynamics without interference from cellular complexity, enabling precise mechanistic studies.

Recombinant Protein Platforms

In recombinant protein-based models, Palbociclib can be used to study direct interactions between CDK4/6 and target substrates, facilitating analysis of binding kinetics, inhibitory potency, and structural dynamics. Researchers can dissect specific molecular mechanisms, including conformational changes and epitope accessibility, to better understand cell cycle regulation.

In Vitro Signaling Pathway Models

Palbociclib supports reconstructed signaling pathways in vitro, enabling the study of feedback regulation, downstream signaling events, and pathway crosstalk. These models allow detailed investigation of temporal kinase activity, phosphorylation events, and regulatory network modulation, providing high-resolution mechanistic insights.

High-Throughput Screening Frameworks

The compound serves as a benchmark inhibitor in high-throughput screening (HTS) platforms, assisting laboratories in evaluating assay sensitivity, reproducibility, and performance consistency. Palbociclib ensures reliable comparison of novel compounds and validation of mechanistic assays across multiple experimental conditions.

Computationally Integrated Models

Palbociclib is compatible with hybrid experimental-computational approaches, where in vitro inhibition data can be combined with molecular docking, predictive simulations, and structure–activity relationship (SAR) analyses. This integration facilitates data-driven mechanistic interpretation, identification of key regulatory nodes, and cross-validation of experimental findings with computational predictions.

Overall, Palbociclib provides a versatile, reproducible, and high-purity tool for laboratories investigating CDK-mediated regulatory networks, kinase inhibition, and cell cycle dynamics. Its compatibility with cell-free, recombinant, signaling, high-throughput, and computational models makes it an essential reagent for mechanistic and molecular research in strictly controlled in vitro environments.

Experimental Design Considerations

When designing experiments with Palbociclib, careful planning is essential to ensure reliable, reproducible, and interpretable data in laboratory research settings. Its behavior in vitro can be influenced by multiple factors, and optimizing experimental parameters is critical for high-quality mechanistic insight.

Concentration and dilution optimization is a primary consideration. Palbociclib should be initially titrated to identify the optimal working concentration for specific kinase assays, signaling pathway studies, or protein interaction experiments. This minimizes non-specific effects and ensures precise target engagement.

Time-dependent experiments are recommended to monitor dynamic inhibitory effects on CDK4/6 activity and downstream molecular events. Multiple incubation intervals allow researchers to assess both rapid and sustained pathway modulation, providing a temporal understanding of mechanistic outcomes.

Control groups and replicates are essential for validating experimental results. Incorporating negative controls, baseline references, and internal standards helps distinguish compound-specific effects from system variability. Technical and biological replicates further strengthen data reliability.

Environmental parameters such as temperature, pH, and buffer composition should be carefully standardized. Minor fluctuations can influence inhibitor stability, binding affinity, and assay sensitivity, potentially confounding mechanistic interpretations. Detailed documentation of all experimental conditions ensures reproducibility and accurate data interpretation.

Finally, orthogonal validation techniques should be considered. Combining Palbociclib studies with spectroscopic analysis, high-resolution imaging, or computational modeling can provide complementary evidence to support mechanistic hypotheses. Multi-omic integration allows correlation of inhibition data with proteomic, transcriptomic, or metabolomic outputs, enhancing data-driven insights.

By systematically addressing these considerations, researchers can optimize the use of Palbociclib as a precise, reliable, and reproducible tool for studying CDK4/6 regulation, kinase activity, cell cycle control, and mechanistic pathway analysis in strictly controlled in vitro experiments.

Laboratory Safety & Handling Guidelines

Palbociclib 125 mg is a high-purity research reagent intended exclusively for in vitro and laboratory mechanistic studies. Proper handling and adherence to safety protocols are essential to ensure researcher safety, experimental reproducibility, and compound integrity.

Personal protective equipment (PPE) is required at all stages of handling. Researchers should wear gloves, lab coats, and protective eyewear to prevent contact with skin, eyes, and clothing. Direct contact with the compound should be avoided, and all transfers or manipulations should be performed using sterile pipettes, tips, and containers rather than bare hands.

Experiments should be conducted in well-ventilated laboratory areas or fume-controlled workstations to reduce the risk of accidental exposure or aerosolization. During preparation or dilution, care must be taken to minimize spills and splashes. Containment devices, such as secondary trays or protective shields, are recommended to maintain environmental safety.

Storage conditions are critical for maintaining chemical stability. Palbociclib should be stored at 2–8°C in tightly sealed, labeled containers, protected from light and moisture. Avoid repeated freeze-thaw cycles to prevent degradation and ensure consistent experimental outcomes.

In the event of a spill, secure the area and follow standard laboratory spill response protocols. Use appropriate absorbent materials, disinfectants, and personal protective measures. All cleanup materials should be treated as laboratory chemical waste in accordance with institutional guidelines.

Waste management is mandatory for unused Palbociclib and all derived solutions. Dispose of them according to institutional chemical waste procedures to ensure compliance with safety and environmental regulations. Proper documentation, including COA and batch identifiers, should accompany storage and disposal activities to support traceability and quality assurance.

Adhering to these guidelines ensures that Palbociclib is handled in a safe, controlled, and reproducible research environment, maintaining its purity and functional activity while safeguarding laboratory personnel.

Integration with Multi-Omic & Computational Studies

Palbociclib is a versatile CDK4/6 inhibitor that can be seamlessly integrated into multi-omic research workflows to provide comprehensive mechanistic insights in strictly controlled in vitro studies. Its high purity and reproducibility make it suitable for proteomics, transcriptomics, and metabolomics investigations, enabling researchers to correlate CDK4/6 inhibition with broader molecular network responses.

In proteomic studies, Palbociclib facilitates the analysis of protein-protein interactions, phosphorylation events, and kinase-substrate dynamics. Researchers can quantify changes in protein activity or signaling pathways in response to inhibitor treatment, supporting mechanistic pathway reconstruction.

Within transcriptomic frameworks, Palbociclib allows researchers to explore gene expression patterns associated with CDK4/6 modulation. By linking transcriptional changes to upstream kinase inhibition, researchers can identify regulatory networks and transcription factor activity influenced by Palbociclib in vitro.

Palbociclib also contributes to metabolomic studies, allowing assessment of metabolite flux, energy balance, and system-level responses in laboratory models. Combining multi-omic datasets provides a holistic understanding of molecular mechanisms and identifies critical nodes and regulatory pathways.

Beyond experimental integration, Palbociclib is compatible with computational modeling, molecular docking, and structure–activity relationship (SAR) simulations. In silico approaches can predict binding stability, interaction specificity, and mechanistic outcomes, complementing experimental observations and enhancing the interpretability of in vitro data.

Integration with multi-omic and computational studies enables cross-validation of findings, facilitating robust mechanistic interpretation and identification of key regulatory molecules. Palbociclib’s consistent formulation and high-quality manufacturing support data reproducibility, multi-layered analysis, and predictive modeling, making it a reliable reagent for advanced mechanistic research.

Overall, Palbociclib acts as a bridge between experimental assays and computational approaches, allowing researchers to conduct integrative molecular investigations, gain high-resolution mechanistic insights, and leverage multi-omic datasets to understand CDK4/6-dependent regulatory networks in vitro.

Things to Note

• Strictly for laboratory research and in vitro studies only.

• Do not use in humans or animals.

• Store in sealed vials at 2–8°C, protected from light.

• Use proper PPE and follow laboratory safety protocols.

• Validate solvent compatibility and assay parameters before experimental use.

• Utilize COA and batch verification for experimental reproducibility.

Keywords

Palbociclib, high-purity CDK4/6 inhibitor, 125 mg powder, in vitro research reagent, laboratory research, kinase inhibition, cell cycle regulation, mechanistic study, protein interaction analysis, signaling pathway research, high-throughput screening reference, multi-omic integration, computational docking compatible, Tumor (compound) Research, structure–function analysis, laboratory research only.

Shipping Guarantee

All shipments of Palbociclib are delivered in secure, research-grade packaging, preventing contamination or damage. Temperature-controlled logistics maintain compound stability during transit. Global shipping is available for research laboratories, with tracking for full visibility.

Trade Assurance

Factory-direct supply ensures batch traceability and analytical verification. Each batch includes COA and documentation, supporting reproducibility. Bulk and wholesale options are available for long-term or high-throughput studies.

Payment Support

Multiple payment options are provided for secure and convenient transactions. Acceptable methods include Credit Card, T/T (Telegraphic Transfer), and encrypted cryptocurrency payments. Flexible payment ensures confidentiality, financial safety, and streamlined procurement.

Disclaimer

Palbociclib 125 mg is intended exclusively for laboratory research and in vitro studies. It is not for human or animal use and must not be applied for clinical, therapeutic, or diagnostic purposes. Researchers must follow institutional safety protocols in controlled laboratory environments.

References

1. PubChem – Palbociclib: https://pubchem.ncbi.nlm.nih.gov/compound/Palbociclib

2. DrugBank – Palbociclib: https://go.drugbank.com/drugs/DB08250

3. NCBI – Protein and Chemical Resources: https://www.ncbi.nlm.nih.gov

4. RCSB Protein Data Bank – Structural Studies: https://www.rcsb.org

5. Wikipedia – Palbociclib: https://en.wikipedia.org/wiki/Palbociclib